Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis
verfasst von:
Helena B. Thomaides-Brears, Naim Alkhouri, Daniela Allende, Mukesh Harisinghani, Mazen Noureddin, Nancy S. Reau, Marika French, Carlos Pantoja, Sofia Mouchti, Donna R. H. Cryer
Approaches to liver biopsy have changed over the past decade in patients with chronic liver disease.
Aims
We conducted a systematic review and meta-analysis on the incidence of all complications and technical failure associated with percutaneous liver biopsy.
Methods
We systematically searched PubMed and the Cochrane Library for cohort studies reporting on complications resulting from liver biopsy published between 2010 and 2020. Studies on participants of any age and sex, who underwent any percutaneous biopsy for non-focal liver disease, were selected. All events except mild pain, minor hematoma, vasovagal episodes, fever and fistula were defined as major complications. Random-effect model meta-analyses with and without covariates were performed, to examine the effect of publication year, patient characteristics, outcome collection, and biopsy type on incidences.
Results
We identified 30 studies reporting on complications resulting from percutaneous liver biopsy procedures (n = 64,356). Incidence of major complications was 2.44% (95% CI 0.85, 6.75), with mortality at 0.01% (95% CI 0.00, 0.11), hospitalization at 0.65% (95% CI 0.38, 1.11), major bleeding at 0.48% (95% CI 0.22, 1.06), and moderate/severe pain at 0.34% (95% CI 0.08, 1.37). Minor complications at 9.53% (95% CI 3.68, 22.5) were mainly pain at 12.9% (95% CI 5.34, 27.9). Technical failure was high at 0.91% (95% CI 0.27, 3.00). Decreasing patient age significantly increased incidence of hospitalization and major bleeding (P < 0.0001). Hospitalization incidence also significantly increased with disease severity.
Conclusions
Incidence of major (2.4%) and minor (9.5%) complications, and technical failure (0.91%) in percutaneous liver biopsies continues.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Biopsy is considered the diagnostic reference for assessment of liver tissue in chronic liver disease. As outlined in 2009 by the American Association for the Study of Liver Disease [1] and confirmed by the British Society of Gastroenterology [2], percutaneous biopsy is the most commonly performed procedure [3], with transjugular biopsies performed in patients more vulnerable to complications, and endoscopic biopsies emerging as a safe alternative. The use of imaging to guide needle positioning or to assist the procedure, by identifying ascites for example, has largely superseded blind procedures in most cases, particularly in pediatric patients [4]. Digitization of slides and the first steps in automation of histological reads have also been reported [5]. Not all facilities have ultrasound (US), computer tomography (CT) or digitization, however, and real-world practice varies widely based on local guidelines.
Assessment of diffuse disease represents the most frequent biopsy indication, including for monitoring patients in drug efficacy trials. Over 2000 biopsies on average are performed per Phase 3 trial [6], as drug trial endpoints and for cohort enrichment, and this translates to > 50,000 biopsies just in current active trials for fatty liver disease where no therapeutics have yet been licensed. For such disease a histological sample representative of the whole liver is required, but biopsy is subject to variability in sampling and interpretation [7‐9].
Anzeige
Liver biopsy is invasive and is associated with potential clinical complications. These influence payer and healthcare costs so accurate estimates of complications are required to inform clinical guidelines. Clear contemporary incidences of such complications are lacking, however. Even now the quoted incidence of biopsy-related death, 0.01% [2], is based on a multi-center retrospective report in Italy [10] from over 30 years ago. Similarly, reported incidence of major bleeding varies widely, from 0% to 5.3%, while pain incidence has been rarely reported on, but can reach 84% [11]. Very recently a scoping review on percutaneous biopsy has highlighted age, inpatient status, and coagulation profile as potential factors contributing to bleeding complications, which were estimated to be < 2% [3]. In contrast a meta-analysis of US-guided percutaneous liver biopsy for diffuse and focal disease reported 0.00% as the pooled incidence of bleeding. However, neither report fully examined all other complications [12].
Here our primary aim was to comprehensively evaluate recent incidence of every major and minor complication in real-world biopsy practice for chronic, non-focal liver disease. We aimed to standardize differences in reporting and examine the impact of risk factors on the incidence of complications. Due to their overwhelming prevalence, we focused on percutaneous liver biopsy procedures. The specific questions we sought to address were: (1) what are the current incidences of all reported complications, (2) are complications influenced by patient characteristics, biopsy procedure, and other study confounders, and (3) what is the technical failure rate of the procedure.
Methods
This systematic review was conducted and reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement [13].
Literature Search
We used free text terms for “liver” and “biopsy” and “complications” or “bleeding” to search the following electronic databases for abstracts published between January 2010 to April 2020: PubMed (including MEDLINE), Cochrane Library, ClinicalTrials.gov, WHO ICTRP including ISRCTN and EU Clinical Trials Register. The search results were combined into a Mendeley database to facilitate reference management. The bibliographic section of selected review articles, including both systematic and narrative articles on the topic, was manually searched for additional relevant articles (grey literature). The last search was performed on 4th April 2020.
Anzeige
Study Selection, Outcome and Covariate Definitions
Studies were included in this review if they met the following criteria:
Study design: prospective or retrospective human cohort studies including randomized control trials (RCTs).
Population: pediatric (infant to 18 years) and/or adult (≥ 18 years) patients with diffuse liver disease, including post-transplant and up to 25% focal disease.
Exposure: any percutaneous liver biopsy (including US-guided, US-assisted, CT-guided, percussion-guided or plugged).
Outcomes: within 3-months from biopsy, clearly reported counts for hospitalization, major and minor complications and technical failure.
Hospitalization events were study author defined serious adverse events and/or non-routine hospitalization events explicitly described, including transfusion. Major complications were defined by type of clinical event even if not associated with new or additional hospitalization or transfusion. Instead, the hospitalization category was used for events associated with new or additional hospitalization. Major complications comprised death, transfusion, major hematoma (subcapsular, intramuscular, intrahepatic, variceal), hemoperitoneum, hemothorax, hemobilia, organ injury, biliary event, pneumothorax, sepsis, moderate or severe pain (requiring follow-up, opiate analgesic or hospitalization, or ≥ 4 on VAS scale). To address and include studies where major bleeding incidence was described without further specification of clinical diagnosis, the major bleeding category was introduced to include these bleeding events, as well as the specified major bleeding complications listed above (subcapsular hematoma, intramuscular hematoma, intrahepatic hematoma, variceal hematoma, hemoperitoneum, hemothorax, hemobilia).
Minor complications were mild pain (self-resolving, "at biopsy site" or < 4 on VAS scale), other hematoma (localized at biopsy site, transthoracic, cervical), vasovagal episodes, fever, arteriovenous fistula. Technical failure was defined as an inability to attain a histological sample or achieve histological assessment.
To assess patient characteristics that may influence complication incidence studies with ≥ 25% patients with either ascites, transplants or cirrhosis were identified to create the covariate category of disease severity. Study covariates considered in the analysis were: publication year, cohort age (pediatric vs adult vs mixed age), severity of disease (chronic vs post-transplant vs cirrhosis vs ascites), outcome collection method (solicited vs spontaneous), biopsy procedure (percutaneous without or with US-guidance). In qualitative analysis, higher risk of bleeding was defined as ≥ INR 1.5 and/or platelet count below 50,000/ml, although these are poor guides to bleeding tendency in those with cirrhosis [14].
We restricted inclusion to English language articles. We excluded studies reporting on biopsy in cohorts with hematopoietic stem cell transplant, sphincterotomy, transcatheter embolization or > 25% focal disease. We excluded studies reporting on transjugular, endoscopic biopsies or biopsies under direct visualization; although if clearly defined outcomes on percutaneous biopsies were included in the same article, the percutaneous subgroup was included as a separate study. If more than one study was reported by the same institute, only the most comprehensive was included.
Data Extraction and Risk of Bias Assessment
The following information was extracted from included studies independently by 2 co-authors and conflicts resolved by discussion: study design, participant characteristics, biopsy procedure details, outcomes reported, timing and method of follow-up, and outcome results. Study risk of bias was assessed through use of the QUIPS (QUality In Prognosis Studies) tool [15], modified based on the Newcastle–Ottawa scale criteria [16], and taking into account the current guidance on meta-analysis of cohort studies [17], to suit the requirements of this review (Supplementary Table 1). The modified tool has six domains: study population; study attrition; study procedure; study confounders; outcome measurement; and outcome reporting. For each domain, the adequacy of reporting by a study was assessed as “yes risk of bias,” “partial,” or “no risk of bias,” by two co-authors. Based on domain assessments by two co-authors and following any conflict resolution, studies were assigned to the following overall categories of risk of bias:
Low risk of bias: describes studies for which all domains had no risk;
Moderate risk of bias: describes studies for which one or more domains are scored as “partial” or one domain is scored as “yes risk of bias”;
High risk of bias: describes studies for which more than one domain is scored as “yes risk of bias.”
The rating of the overall quality of the evidence from this review was undertaken in consideration of current guidance on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach [18]. Sensitivity analysis was also carried out by separate meta-analysis of percutaneous biopsy complications in single-center studies and from all pediatric only studies.
Statistical Analysis
Data were analyzed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions [17].
Anzeige
Only 4 studies reported on all complications, so for each analysis we included the subset with complete cases in the outcome and fitted random effects meta-analysis models to the data to derive pooled incidences and 95% CI and sampling from a minimum of 6 studies. We assumed the incidence followed a binomial-normal distribution with a random intercept, as recommended for proportion-based analysis with low counts of events resulting in random dispersion of data based on the sample size [19]. Studies with no events were problematic and did not allow the calculation of study sampling variances. To address this, zero events were replaced with 0.5, also increasing the total sample size by 1. Statistical heterogeneity between studies was assessed using the likelihood ratio test [20] and Cochrane I2 statistic cut-offs, with 50% to 90% potentially representing substantial heterogeneity and 75% to 100% representing considerable heterogeneity [17].
Forest plots were plotted to show the fitted random-effects model. Funnel plots of sample size by log odds were plotted to investigate the presence of publication bias or the effect of small study size by visual inspection [19].
The mixed effects model with study level covariates accounted for at least part of the heterogeneity in true effects and were explored for systematic differences between the studies. All study level covariates were transformed to the mean. This analysis was restricted to those outcomes with meaningful funnel plots. The aggregated influence of study level covariates on pooled incidences was tested via the Q Moderator-test (QM-test), while the influence of each covariate was also tested individually. Significance threshold of P-value tests was set at 0.05, though true significance for covariate influence was set to < 0.001.
All data analyses were conducted using R studio version 4.0.0.
Anzeige
Results
Study Selection and Quality Assessment
We screened a total of 5,973 studies and selected a total of 140 studies for full text evaluation. Following review of the full study articles, a total of 30 studies (28 articles), representing 64,356 percutaneous biopsies, were judged to meet the inclusion criteria for this systematic review and meta-analysis. The most common reasons for exclusion were the absence of biopsy complication numbers (n = 52) or studies that were qualitative reviews (n = 28) (Fig. 1, Supplementary Table 2). We excluded one study reporting on biopsy under direct visualization, one study reporting on multiple procedure types without distinction, 3 studies with endoscopic and 4 studies on transjugular biopsies, as these studies were too few to enable valid meta-analysis. We also excluded studies for which full articles not available (n = 10), if they were not in English (n = 4), they duplicated other studies (n = 5) or were out for scope (n = 5).
Fig. 1
PRISMA diagram summarizing study selection process
×
The QUIPS (QUality In Prognosis Studies) tool [15], modified based on the Newcastle–Ottawa scale criteria [16] and current guidance on cohort studies [17], were used to evaluate the quality of the studies. Most studies (17) were high quality, with 12 deemed to be of moderate quality and 1 judged to be of low quality (Supplementary Table 3).
Study and Cohort Characteristics
Most studies were retrospective (20/30, all except [21–29]). Most were single-center accounts, with 3 being multi-center studies that nevertheless represented the majority of samples (56,058 of 64,356 biopsies; Table 1). The overall study period represented was 1998–2017, with Asia–Pacific represented by 5 studies, Europe by 12, USA by 8 and Asia Minor by 5 studies.
PLP: mean age 46 years (10 years, 79 years); 11% pediatric; 59% male
Transjugular (TJLB) or plugged-percutaneous (PLP)
PLB: platelets 60,000- 100,000/mL- or INR 1.4–2, or pediatric ascites. Local anesthesia in adults but sedation in pediatric. Experienced interventional radiologist
AE, deaths, SAE
At hospital 12 h or 24 h and discharged if no symptoms. Discharge information and 2-week biopsy result consultation. [spontaneous]
Included: platelet count over 50,000/μL, INR < 1.5. Antiplatelet (clopidogrel/ticlopidine) and anticoagulant agents were suspended or reverted. Conscious sedation (midazolam and meperidine 25 mg) and local anesthetic medication (5 ml of 1% lidocaine). Randomized for 3 recovery positions. Experience not reported
AE, deaths, SAE
4 h observation period for solicited adverse events. Electronic record evaluation 7 days post-biopsy. [solicited]
20% < 1 years; 60% 1–6 years; 20% 6–14 years . Male/female not reported
Blind, US-assisted, percutaneous
Included: patients with PT < 3 s with/without correction by vitamin K and platelets > 70,000/μL. Sedation in 85% of patients; local anesthesia in 100% of patients. Experience not reported
AE, deaths, SAE
Vital signs recorded hourly for the first 4 h, two hourly for the following 4 h and then at 24 h after the procedure. US at 24 h post-procedure. In those with irritability or pain, CXR rule out the possibility of small pneumothorax. [solicited]
Percussion-guided percutaneous (4.9% with US-guidance)
Included: platelet count over 40,000/μL, INR < 2, Hgb .8.0 g/dL. Anticoagulants discontinued 3 days before biopsy. Local anesthesia (Rovicavaine). Experience not reported
AE, deaths, SAE
Monitoring for 4–6 h then discharge in the absence of complications. [spontaneous]
Suspected rejection of living donor liver transplants
50 years (range 4–68 years); 78% male
Plugged percutaneous with US-guidance
INR < 2 with vitamin K administration, some biopsies proceeded with caution despite being out of range, using N-butyl cyanoacrylate. Sedation not reported. Interventional radiologists with more than 12 years of experience
AE, deaths, SAE
Observation for 1 h and imaging not routinely performed without clinical signs. Medical record review. [spontaneous]
US-guided or assisted percutaneous (fine needle aspiration cytology, 0.3%, or cutting biopsy, 28.9%, or aspiration with Menghini, 70.8%)
Included: platelets ≥ 70,000/μl, Quick’s test value ≥ 70%, PTT < 50 s; some deviations reported. No use of anti-coagulants. Sedation not reported. 39% performed by experienced (> 150 liver biopsies) and 61% by inexperienced clinicians
AE, deaths, SAE
Monitored for 4 h with US for all but fine needle aspiration cytology. [solicited]
Transjugular (TJLB) and percutaneous preceded by US exam (PLB)
Hemodynamic criteria not defined. Local anesthesia for all biopsies. 88% performed by experienced (> 150 liver biopsies) or 12% by inexperienced clinicians
AE, deaths, SAE. Only pain specified from minor complications, though all reported
After the procedure, patients were monitored for an additional 2 h. Anxiety assessed 1 day before and 1 day after procedure. [solicited]
Included: ≥ 75,000 mm3 for platelets, ≥ 50% Prothrombin. No sedation data recorded. Clinicians with more than 500 liver biopsies in the previous 10 years
Retrospective review; 2008–2014; all complete database records
35.9% viral; 25% NASH; 13.4% ASH; 34.5% other non-focal disease
Mean age 51 years (range 14–85 years); 50% male
Percutaneous
Mean INR 1.33–1.5 and platelets 156–209*10^9/L suggest few patients with severe coagulopathy. Sedation and experience not reported
Death and specific major bleeding events (acute hemoperitoneum, drop in hematocrit requiring transfusion or embolization)
Electronic medical records for the period of 2 weeks prior to biopsy to 4 weeks after biopsy. Also records from 1 month-post biopsy clinic. [spontaneous]
Compensated chronic hepatitis C and nonresponse to prior treatment with interferon with or without ribavirin. 39.9% cirrhosis; 41.0% varices
Mean age 52 years; 72% male; Mean BMI 30 kg/m2
Percutaneous
Included: platelet counts ≥ 50,000/mm3. Mean INR 1.1. No NSAID or aspirin 7 days before biopsy. All with local anesthesia. 60% had conscious sedation with short-acting benzodiazepines. Hepatologists, with 20% biopsies performed by supervised gastroenterology or hepatology fellows
AE, deaths, SAE
Same day discharge with close monitoring in 20%. Clinic within 3 months of biopsy. Medical record review for complications within 30-days of biopsy. [spontaneous]
Only parenchymal disease, included both transplants and native livers but numbers not reported
Mean age 56 years (range 15d to 96 years with 18 years SD); 55% Male
US-guided percutaneous
Included: platelet count over 50*10^9/L, international normalized ratio (INR) < 1.6. Minority of patients had taken Plavix prebiopsy. Aspirin not excluded. Sedation and experience not reported
Only grade 3 hemorrhage (an event for which a transfusion, an interventional radiology procedure, or an operative intervention is indicated) & deaths. [NCI, 2006]
Phone call at 1, 2 or 3 days after biopsy and second review at 3 months for delayed complications. [solicited]
Median age 9 years (range 1 months–18 years); 53% male
US-guided percutaneous
Included: platelet count over 50,000/μL, international normalized ratio (INR) < 1.5. Several procedures were, however, performed in patients with higher INR and lower platelet counts (lowest platelet count: 29 G/L; highest INR: 1.7). 98% general anesthesia; 2% local anesthesia. Experience not reported
AE, deaths, SAE
Monitored for at least 6 h after the procedure, including assessment every 30 min for hemodynamic status. In cases of symptoms, or an immediate identified complication, a control ultrasound evaluation was performed after the first 6 h and monitoring extended for 12 to 24 h. [solicited]
Prospective research trial; 2004–2010; Not reported
NAFLD/NASH (40%), HCV (26%), AIH/PSC/PBC (14%), ALD (14%). 14.5% patients had established cirrhosis
Mean age 51 years; 56.9% male
US-guided percutaneous
Included: platelet count > 80,000/μL and INR < 1.3. Local anesthetic (lidocaine). Performance of 45 biopsies under direct supervision before independent performance, in presence of consultant radiologist
AE, deaths, SAE
Not reported: immediate and overnight effects described. [spontaneous]
Included: INR < 1.5 and platelet count > 50*10^9/L.7.2% received transfusion/plasma/rFactor VII to optimize coagulation profile. General anesthesia. Experience not reported
AE, deaths, SAE
Monitored at 6 h for signs of pain or bleeding. Followed up with US and extended observation to 24 h if clinical signs. [solicited]
Included: INR < 1.5 and platelet count > 50*10^9/L. Local anesthesia (1% xylocaine containing 1:100,000 adrenaline). All patients metoclopramide: placebo with saline vs with pethidine. Performed both by the consultant and advanced trainee in gastroenterology
AE, deaths, SAE
Monitored for 4 h with additional pain evaluations. Followed up with phone call at 24 h. [solicited]
Patient questionnaire 2 h before biopsy and monitoring for 4 h before hospital discharge. 24 h assessment with US and patient questionnaire. [solicited]
Corrected INR ≤ 1.5 and platelet count > 50 × 10^9/L. Local anesthesia (2% lidocaine). Imaging physician assistants with 2 and 14 years of intervention experience in tandem with abdominal imaging fellows or attending radiologists
AE, deaths, SAE
Monitoring for 4 h or until discharge. Follow-up call at 24 h. [solicited]
INR ≤ 1.5 and platelet count > 50*10^9/L within 30 days pre-biopsy. Conscious sedation (midazolam and fentanyl). Radiologists, all of whom were either fellowship trained in abdominal imaging and intervention or had at least 10 years of experience
AE, deaths, SAE
Monitoring for 4 h with further overnight observation if clinical signs or symptoms. Medical record review for events within 15 days of biopsy. [spontaneous]
Median age 5 years (range 22 days–18 years). Not reported
US-guided percutaneous
Included: platelets ≥ 70,000/μl, INR < = 1.7 with hemodynamic correction pre-biopsy. General and local anesthesia. Operators who had not performed pediatric liver biopsies previously were supervised by an experienced colleague during the first procedures
AE, deaths, SAE
Monitoring closely within 2 h and every 4 h overnight when US performed. [solicited]
Eighteen of 30 studies were performed exclusively on adults, while 4 were mixed age but mainly in adults. Eight studies were on pediatric patients and almost all utilized sedation (7/8). In contrast, sedation was reported in only 3 of 18 studies with adult-only patients. The majority of studies (18/30) were on less severe disease, while 10 included investigation of transplants (Supplementary Table 5). Half of the studies (15/30) utilized US to guide the percutaneous biopsy procedure.
Anzeige
Major Complications
The pooled incidence of major complications for percutaneous biopsies was 2.44% (95% CI 0.85, 6.75) (Table 2; Figs, 2, 3, 4, 5, 6, 7, 8). Mortality occurred at 0.01% (95% CI 0.00, 0.11), major bleeding at 0.48% (95% CI 0.22, 1.06) and moderate or severe pain at 0.34% (95% CI 0.08, 1.37). Incidence of non-routine hospitalization was 0.65% (95% CI 0.38, 1.11). Other specific complications occurred rarely, ranging from 0% (95% CI 0.00, 0.79) for biliary events and 0.11% (95% CI 0.02, 0.53) for major hematomas (subcapsular, intramuscular, intrahepatic or variceal).
Fig. 2
Forest plots showing pooled incidence (as %) for hospitalization (a) and all major complications (b)
Fig. 3
Forest plots showing pooled incidence (as %) for major bleeding (a) and moderate/severe pain (b)
Fig. 4
Forest plots showing pooled incidence (as %) for major hematoma (a) and hemoperitoneum (b)
Fig. 5
Forest plots showing pooled incidence (as %) for death (a) and transfusion (b)
Fig. 6
Forest plots showing pooled incidence (as %) for hemobilia (a) and hemothorax (b)
Fig. 7
Forest plots showing pooled incidence (as %) for pneumothorax (a) and biliary events (b)
Fig. 8
Forest plots showing pooled incidence (as %) for sepsis (a) and organ perforation (b)
Table 2
Incidence of major complications, minor complications and technical failure
Event
Pooled incidence (95% CI)
I2 (%)
tau
Heterogeneity P value (LRT-test)a
Included studies
Total events/Total biopsies
By population ageb
Total events/total biopsies
Major complications
Biliary events
0.00% (0.00, 0.79)
81
2.69
0.7079
27
4/9341
A: 0/7443; M: 0/306; P: 4/1682
Death
0.01% (0.00, 0.11)
76
2.06
0.5157
29
12/64214
A: 9/60390; M: 0/2142; P:3/1682
Hemobilia
0.01% (0.00, 0.54)
38
1.02
0.9997
25
3/8797
A: 3/7137; M: 0/306; P: 0/1354
Sepsis
0.02% (0.00, 0.51)
24
0.77
0.9768
24
2/8608
A; 1/7159; M: 0/306; P: 1/1143
Hemothorax
0.03% (0.01, 0.10)
0
0.00
0.9995
26
3/9125
A: 2/7137; M: 0/306; P: 1/1682
Organ perforation
0.03% (0.01, 0.10)
0
0.00
0.9999
26
3/9013
A: 2/7353; M: 0/306; P: 1/1354
Pneumothorax
0.04% (0.02, 0.11)
0
0.00
0.9999
27
4/9341
A: 4/7353; M; 0/306; P: 0/1682
Hemoperitoneum
0.06% (0.01, 0.39)
84
2.05
0.0002
26
27/9125
A: 15/7137; M: 0/306; P: 12/1682
Transfusion
0.08% (0.02, 0.41)
80
1.96
< 0.0001
25
20/8057
A: 7/6582; M 0/306; P: 13/1169
Major hematomac
0.11% (0.02, 0.53)
90
2.33
< 0.0001
25
39/8797
A: 14/7137; M: 0/306; P: 25/1354
Moderate/severe pain
0.34% (0.08, 1.37)
96
2.41
< 0.0001
21
132/8346
A: 112/7012; P: 20/1334
Major bleeding
0.48% (0.22, 1.06)
94
1.58
< 0.0001
30
356/64356
A: 293/60390; M: 14/2284; P: 49/1682
Hospitalization
0.65% (0.38, 1.11)
86
1.01
< 0.0001
30
361/64356
A: 318/60390; M: 14/2284; P: 29/1682
All major complications
2.44% (0.85, 6.75)
97
1.86
< 0.0001
15
184/6013
A: 153/5831; P: 31/182
Technical failure
0.91% (0.27, 3.00)
97
2.17
< 0.0001
17
166/6801
A: 90/4893; M: 5/306; P: 71/1602
Minor complications
Vasovagal episodes
0.15% (0.03, 0.66)
89
2.28
< 0.0001
23
34/7781
A: 33/6432; M: 0/306; P: 1/1043
Other hematomad
0.19% (0.03, 1.14)
97
2.55
< 0.0001
15
80/7177
A: 10/5925; P: 70/1252
Other minor eventse
0.27% (0.07, 1.03)
94
2.51
< 0.0001
23
65/8265
A: 29/6277; M:1/306; P: 35/1682
Mild pain
12.9% (5.34, 27.9)
99
2.10
0.7079
19
704/7247
A: 645/6241; P: 59/1006
All minor events
9.53% (3.68, 22.5)
99
1.69
< 0.0001
11
424/6242
A: 381/5649; P: 43/593
aIn bold are significant P values, indicating significant heterogeneity between studies
bA: adults; M: mixed age group; P: pediatric patients
dHematoma at biopsy site, transthoracic, cervical hematoma
eArteriovenous fistula, fever, other (not pain or vasovagal episodes)
×
×
×
×
×
×
×
While not a major complication, incidence of technical failure during biopsy procedures has significant consequences for both patient and clinician. Technical failure occurred at 0.91% (95% CI of 0.27, 3.00), based either on the failure to attain a histological sample at all or a sample without sufficient quality for scoring (Fig. 9). Potential publication bias was investigated with funnel plots (Supplementary Figs. 1–2) and identified the absence of bias for hospitalization, major complications, moderate/severe pain and technical failure.
Fig. 9
Forest plots showing pooled incidence (as %) for all minor complications (a) and technical failure (b)
×
Minor Complications
Minor complication incidence was 9.53% (95% CI 3.68, 22.5). Mild pain was the most frequent minor complication [12.9% (95% CI 5.34, 27.9), Table 2; Figs. 9, 10 and 11]. Potential publication bias was identified for all minor complications (Supplementary Fig. 3).
Fig. 10
Forest plot showing pooled incidence (as %) for mild pain (a) and vasovagal episodes (b)
Fig. 11
Forest plot showing pooled incidence (as %) for other minor complications (a) and other hematoma (b)
×
×
Impact of Patient Age and Disease Severity on Complication Incidence
Fitting mixed effects models based on study-level covariates reduced the heterogeneity across studies for most complications, with substantial or complete reduction for hospitalization, major bleeding, transfusion, major hematoma and technical failure (Table 3).
Table 3
Impact of publication year, population age, disease severity, outcome collection (solicited or spontaneous) and biopsy type (percutaneous with or without US-guidance) on incidence of complications
Event
P valuea
Original I2 (%)
Residual I2 (%)b
QM-test of covariates
Publication year
Population age
Disease severity
Outcome collection
Biopsy type
Residual heterogeneity (LRT-test)
Hospitalization
< .0001
< .0001
<0.0001
0.0007
0.0033
0.0833
0.0004
86
0
Moderate/severe pain
0.1555
0.1154
0.2451
0.3362
0.5547
0.0311
< .0001
96
87
Major bleeding
< .0001
0.4799
< .0001
0.5294
0.1175
0.0892
< .0001
94
57
Transfusion
0.0306
0.7782
0.0016
0.9402
0.9512
0.1267
0.0561
80
41
Major hematomac
0.0780
0.2823
0.0191
0.7475
0.7131
0.2789
< .0001
90
70
Other hematomad
0.0177
0.7460
0.0586
0.8184
0.2373
0.6478
< .0001
97
85
All major events
0.2273
0.1469
0.2198
0.3229
0.4015
0.8049
< .0001
97
88
Technical failure
< .0001
< .0001
0.0015
0.0230
< .0001
0.1278
< .0001
97
58
Mild pain
0.0002
< .0001
0.7771
0.6829
0.7900
0.1901
< .0001
99
96
Vasovagal episodes
0.1625
0.3345
0.1185
0.6103
0.9617
0.2523
< .0001
89
75
Other minor eventse
0.0027
0.9610
0.0160
0.9305
0.0382
0.0207
< .0001
94
77
All minor
< .0001
0.0002
0.0769
0.8692
0.1990
0.0613
< .0001
99
90
aIn bold are significant P values and highlighted in italics are those below the 0.001 significance threshold
dHematoma at biopsy site, transthoracic, cervical hematoma
eArteriovenous fistula, fever, other (not pain or vasovagal episodes)
Decreasing population age significantly increased the incidence of major bleeding complications, with odds increasing fourfold in studies including pediatric patients or 16-fold in pediatric only reports (P values < 0.0001; Tables 3 and 4). Similarly, for hospitalization, incidence was by twofold higher in studies including pediatric patients and 3.8-fold higher in pediatric only cohorts. This was corroborated by the frequency of all events reported in pediatric studies which was by far higher than in adult only studies (Table 2). Incidence of complications in the subset of pediatric only studies confirms this, with hospitalization incidence at 1.41% (0.57, 3.47) and major bleeding at 2.15% (0.68, 6.57) (Supplementary Table 4). In addition, hospitalization incidence was also impacted by the severity of the underlying disease, so that odds of hospitalization increased 1.25-fold in studies with mainly post-transplant patients, 1.56-fold in patients with ascites and 1.95-fold in cirrhotic patients (Tables 3 and 4).
Table 4
Estimates of odds with 95% CI showing potential contribution of individual covariates on the incidence on complications
Event
Odds estimate (95% CI) by covariatea
Publication year
Population age
Disease severity
Outcome collection
Biopsy type
Hospitalization
1.15 (1.08, 1.22)
2.22 (1.62, 3.04)
1.25 (1.10, 1.43)
0.47 (0.28, 0.78)
0.62 (0.36, 1.07)
Moderate/severe pain
1.47 (0.92, 2.35)
0.42 (0.10, 1.83)
2.01 (0.49, 8.24)
0.51 (0.06, 4.80)
11.5 (1.25, 105)
Major bleeding
1.07 (0.91, 1.25)
4.00 (2.36, 6.77)
0.85 (0.51, 1.43)
0.48 (0.19, 1.21)
0.48 (0.21, 1.13)
Transfusion
0.96 (0.68, 1.35)
5.35 (1.89, 15.2)
0.96 (0.33, 2.84)
0.94 (0.12, 7.63)
0.22 (0.04, 1.55)
Major hematomab
1.22 (0.86, 1.73)
3.52 (1.23, 10.0)
1.23 (0.36, 4.30)
1.63 (0.13, 21.4)
0.36 (0.06, 2.33)
Other hematomac
1.08 (0.69, 1.71)
3.59 (0.96, 13.4)
1.21 (0.25, 5.80)
10.3 (0.22, 490)
0.52 (0.04, 8.75)
All major events
1.31 (0.92, 1.88)
2.15 (0.64, 7.23)
1.93 (0.53, 7.02)
3.71 (0.18, 78.9)
0.75 (0.08, 7.78)
Technical failure
1.77 (1.43, 2.18)
2.82 (1.49, 5.32)
0.38 (0.16, 0.88)
0.07 (0.03, 0.19)
2.37 (0.79, 7.19)
Mild pain
1.78 (1.34, 2.37)
0.89 (0.39, 2.04)
1.22 (0.48, 3.12)
1.29 (0.21, 8.10)
2.51 (0.64, 9.86)
Vasovagal episodes
1.21 (0.83, 1.76)
0.29 (0.06, 1.39)
0.70 (0.18, 2.79)
1.07 (0.09, 13.6)
3.61 (0.41, 32.3)
Other minor eventsd
1.00 (0.74, 1.35)
3.47 (1.27, 9.51)
0.94 (0.21, 4.30)
14.5 (1.16, 180)
0.08 (0.01, 0.67)
All minor
1.97 (1.39, 2.80)
2.2 (0.92, 5.23)
0.95 (0.46, 1.93)
0.37 (0.08, 1.72)
3.43 (0.95, 12.5)
aIn bold are those with significant P values and highlighted in italics are those below the 0.001 significance threshold
cHematoma at biopsy site, transthoracic, cervical hematoma
dArteriovenous fistula, fever, other (not pain or vasovagal episodes)
No significant impact was observed as a result of US-guidance in the biopsy (biopsy type was below the 0.001 significance threshold in Tables 3 and 4), perhaps because many studies used US, even if only to assist ahead of the biopsy rather guide during biopsy. The year of publication impacted incidence reported for hospitalization, technical failure, mild pain and minor complications (Tables 3 and 4). Technical failure was impacted by the method of complication recording, so that odds of technical failure reduced by ninefold in studies were recording of complications was solicited rather than spontaneously reported by the patient (Tables 3 and 4).
Other Confounders
While we extracted data for additional confounders (BMI, higher risk of bleeding and sedation, operator experience), these parameters were insufficiently reported on (4/30, 26/30, 19/30 and 16/30 studies, respectively) for full quantitative analysis (Supplementary Table 5). Nevertheless, a trend was seen such that hospitalization occurred more frequently in cohorts with higher bleeding risk and potential coagulopathy (77/9094 with healthy INR or platelets versus 26/1873 with poor coagulation profile). This same trend was also observed for major bleeding, with more frequent events in studies including patients with higher bleeding risk (79/9094 versus 19/1873). In contrast, hospitalization incidence appeared similar whether sedation was included or not (53/4955 with sedation versus 20/2064 with only local anesthetic), but major bleeding was more frequent with sedation (60/4955 versus 10/2064).
Sensitivity Analysis
Almost all studies were single-center studies thus potentially increasing the overall risk of bias, even though they tended to be smaller studies. In separate meta-analysis of complications from single-center studies (27/30 studies representing 8298 biopsies, Supplementary Table 6), most incidences remained very close to the original analysis that included multi-center studies. However, the incidences of major complications [3.04% (95% CI 0.97, 9.11)], technical failure [1.83% (95% CI 0.76, 4.33)], mild pain [16.6% (95% CI 6.97, 34.7)], other minor events [0.37% (95% CI 0.10, 1.42)] and all minor complications [13.1% (95% CI 4.82, 31.1)] were higher in the single-center analysis due to lack of relevant event reporting in the multi-center studies.
Quality of Evidence
Based on the GRADE approach [18], we found the quality of evidence for cohort age as a prognostic predictor of biopsy complications to be high and for disease severity to be moderate. The quality of evidence for death, hemoperitoneum, hemobilia, hemothorax, organ perforation, pneumothorax, sepsis and biliary complications were all judged to be low due to the sparse number of events or small number of reporting studies. Technical failure lacked consistency in sampling methods across studies. Major bleeding, hematoma, major complications and hospitalization were judged to have high quality evidence due to the frequency of reporting and the removal of potential bias following inclusion of cohort characteristics in the analysis. Sedation during biopsy was least reported and was considered the main source of potential bias.
Discussion
This systematic review and meta-analysis describe accurate, contemporary incidences for all complications reported to result from percutaneous liver biopsy, in 16 individual clinical categories. Additionally, incidences of hospitalization and technical failure have for the first time been provided following meta-analysis rather than based on local, single-center reports. These incidences provide current standardized figures for assessment of the impact that continued inclusion of liver biopsy in clinical care has on diagnosis, staging and monitoring of chronic liver disease. At 24 major complications per 1000 patients and 90 minor complications per 1000 patients, these current incidences on the most commonly performed biopsy procedure are substantial.
Our updated analysis has confirmed that death incidence is 0.01%. This represents 12 reported deaths in 64,356 biopsy procedures, and concurs with original reports from 1986 [10]. Additionally, hemoperitoneum, hemobilia, hemothorax, organ perforation, pneumothorax, sepsis and biliary complications continue to be rare [3, 12]. The updated incidence of major bleeding at 0.48% (95% CI 0.22, 1.06) is in line with a 2019 scoping review for US-guided percutaneous biopsies quoting a range between 0.1% and 4.6% [3]. Incidence of major hematoma reported in our work is substantial [0.11% (95% CI 0.02, 0.53)], as is that of minor hematoma [0.19% (95% CI 0.03, 1.14)]. Reporting of minor hematoma was absent in many of the articles in our review (reported in 17/39 studies) and ultrasound follow-up of biopsied patients was not standard procedure in most studies. Thus, the incidence of hematoma is likely to be higher than presented here and changes to practice to standardize follow-up are advocated.
Both major (0.48%) and minor (0.19%) bleeding in our study occurred more frequently than either major bleeding (0.00%) or minor bleeding (0.00%) in a meta-analysis of US-assisted percutaneous biopsies with a wider study period (1978–2017) [12]. That work included studies of focal disease patients (24/51 cited articles), where sampling occurs during surgery and is targeted to the tumor area. Just over half of the included articles in that meta-analysis were published before 2010 (26/51) and studies without US were for the main absent, thus limiting overlap with this work. We found no evidence in our analysis that US assistance significantly reduced complication rates, precluding that as the explanation of differences in incidence. Instead, there was a fundamental limitation in the earlier work [12] which was that no adjustment of sample size or study selection was made to account for gaps in reporting, thus giving rise to negligible complication incidences. In contrast, in the present work major bleeding included specific, clinically defined bleeding events and study selection was adjusted by complication category. This was to reduce subjectivity resulting from differences in local hospital guidelines and reporting, as our qualitative review revealed that classification of major, mild and “non-significant” events varied widely between studies, and details of clinical follow-up for complications were infrequently reported.
We also report higher values for pain (0.34% for moderate/severe pain and for 12.9% mild pain) compared to the 0.00% incidence in that earlier meta-analysis [12] for the reasons stated above regarding scope and methodology. While frequent, pain was reported in only 21 of 30 studies included in our work and its incidence varied most between studies. Additionally, sedation and/or analgesia was not sufficiently reported for quantitative assessment of its impact on patient pain. Several studies introduced the VAS scale and ensured consideration of this complication by solicited questionnaires. Pain is difficult to assess objectively and is potentially affected by recall bias and the frequency of follow-up [30]; nevertheless, to the patient this complication is a key consideration and would affect the interaction with the clinician. Improvements in clinical recording of pain and prospective studies investigating in detail the quality, nature and duration of pain are required to enable fully informed patient consent.
Technical failure at 0.91% can indirectly affect biopsy complications, as well as patient diagnosis and disease monitoring [31]. Here we found that studies in which reporting of complications from the patient were solicited by the clinical team, had lower odds of technical failures, and we speculate that this was indicative of exceptional care for patient well-being. In our review, sample adequacy was inconsistently reported across studies (5–10 portal tracks, 12–18 mm, number of fragments) and needle passes varied (2–6) or were infrequently reported so firm conclusions as to causes cannot be drawn. Nevertheless, the incidence reported here is much lower than that reported in a meta-analysis of endoscopic US-guided biopsies (10% with inadequate specimen) [32].
Until this work, there was weak evidence to support that age, coagulation status and comorbidities impact the incidence of percutaneous liver biopsy complications [3]. On fuller analysis we find that incidence of hospitalization (defined by additional, non-routine care including severe adverse events) and major bleeding increased most dramatically in pediatric patients. The same conclusion was drawn when the few transjugular and endoscopic biopsy studies identified during this systematic review were included (Thomaides-Brears unpublished). In addition, increased odds of hospitalization were observed in patients with more advanced disease. Thus, patients with cirrhosis are 4 times more likely to be hospitalized after biopsy, compared to patients with earlier stage disease such as NAFLD. While not investigated in this work, complications also arise in non-liver disease indications where liver biopsies are the diagnostic method, with transfusions reported in 25–30% during pre-recovery or pre-surgery biopsy in liver transplant donors [33]. In percutaneous liver biopsy to pre-empt liver damage in pediatric hematopoietic stem cell transplant patients, 17% exhibited mild pain and/or minor hematoma [34]. These findings advocate avoidance of liver biopsy as a recurring event, although incidences reported here are lower than for renal biopsies, in which hematomas occur in 11% and mild pain in 4.3% of patients [35]. While others have found that sedation increased bleeding due to resulting hypoxia and lower hematocrit [36], there was insufficient reporting for us to draw significant conclusions, though there was a trend towards this.
The limitations of this study include the residual heterogeneity in incidences between studies that reduce the quality of the evidence for some events, particularly for rare events such as death and transfusion, and to which reporting bias is a key contributor. Unaccounted risk factors that might explain these limitations are differences in needle type and size, and technical expertise for all procedures, which were too variable to accurately include in this meta-analysis. Other differences between procedures such as plugged or blind biopsies could also account for the heterogeneity. Nevertheless, inclusion of cohort age, disease severity, outcome collection details and publication year as covariates in our analyses removed heterogeneity completely for the incidence of hospitalization and reduced the level of heterogeneity for major bleeding and hematoma. Future applications of this work could include the derivation of a risk score to predict the probability of biopsy complications that takes account of cohort characteristics as prognostic factors. Addition of BMI, a risk factor for fatty liver disease outcomes [37] would be a very relevant risk factor.
In conclusion, this study provides current incidences for complications resulting from percutaneous liver biopsy procedures performed for patients with chronic liver disease; 2.4% for major and 9.5% for minor complications. We believe this data will inform future decisions in clinical care for such patients and highlight the need for more clearly defined formal indications with both non-invasive techniques and liver biopsies as part of diagnostic algorithms. These data should be included in future health economic analyses aiming to inform clinical guidelines and reduce adverse patient outcomes.
Acknowledgments
The authors wish to gratefully acknowledge the contributions of David DeBrota, Tom Nichols, Trit Garg, Sam Nussbaum, Laura Herdman, Lewis Jenkins, Gemma Greenall, Amna Soomro, Ma’Leah Dunn, Maria Salazar, Louise Tetlow, Matt Kelly and Rajarshi Banerjee in critical review and preparation of the final manuscript.
Declarations
Conflict of interest
No funding was received for this work. HTB, MF, CP and SF are employees of Perspectum Ltd, a privately funded commercial enterprise that develops medical devices to address unmet clinical needs, including LiverMultiScan®. DRHC is an employee of the Global Liver Institute, a non-profit organization. MN has been on the advisory board for Gilead, Intercept, Pfizer, Fractyl, Novartis, Allergan, Blade, Echosens, EchoSens North America, OWL, Siemens, Roche diagnostic and Abbott; Speaker: Abbott, Echosens, Intercept. MN has received research support from Allergan, BMS, Gilead, Galmed, Galectin, Genfit, Conatus, Enanta, Novartis, Shire and Zydus; MN is a minor shareholder or has stocks in Anaetos and Viking. All other authors have nothing to disclose.
Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis
verfasst von
Helena B. Thomaides-Brears Naim Alkhouri Daniela Allende Mukesh Harisinghani Mazen Noureddin Nancy S. Reau Marika French Carlos Pantoja Sofia Mouchti Donna R. H. Cryer
